On October 11, 2019 Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, reported that the company will present at the 5 th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:40 AM ET (Press release, Axial Biotech, OCT 11, 2019, View Source [SID1234540985]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 11, 2019 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, reported that company management will be attending the BIO Investor Forum to be held on October 22-23 at the Westin St. Francis, San Francisco (Press release, IMV, OCT 11, 2019, View Source [SID1234540966])estor Forum and Webcast Oct. 23 5:00 PM PST
A live webcast of this presentation will be available under "Events, Webcasts and Presentations" in the investors section of IMV’s website and a replay will be available approximately one hour after the presentation. Afterwards, it will be available for approximately 30 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 11, 2019 Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, reported that the company will present at the 5 th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:40 AM ET (Press release, Axial Biotech, OCT 11, 2019, View Source [SID1234540968]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 11, 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, reported that clinical data on the Company’s lead product candidate eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, will be presented at two industry conferences in October and November 2019 (Press release, Immutep, OCT 11, 2019, View Source [SID1234540969]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference:

World Immunotherapy Congress as part of Festival of Biologics 2019

Dates:

October 15-17, 2019 (Tuesday, 15th October/ 2.50 p.m. CET)

Venue:

Basel Congress Centre, Basel, Switzerland

Presentation Title:

A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology – mature results of TACTI-mel

Presenter:

Frédéric Triebel, CSO & CMO of Immutep

Conference:

34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)

Dates:

November 6-10, 2019 (Friday, November 8th, 7.00am – 8.00pm EST)

Venue:

Gaylord National Hotel & Convention Center in National Harbor, 201 Waterfront St, Forest Heights, MD 20745, USA

Title:

Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab

Poster Number:

343

Authors:

J. Peguero, E. Felip, B. Doger, M. Marjem, E. Carcereny, T. Clay, P. Bajaj, M. Krebs, F. Triebel
All presentations will be made available on the Company’s website at View Source

On October 10, 2019 Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, reported that it will present the first clinical data from its Phase 2 development program with novel, tumor-selective anti-EGFR ADC AVID100 at the 10th Annual World ADC in San Diego (Oct. 8 – 11) (Press release, Forbius, OCT 10, 2019, View Source [SID1234540933]). AVID100 clinical data will also be featured in an upcoming poster presentation at the AACR (Free AACR Whitepaper)-NCI-EORTC meeting in Boston (Oct. 26 – 30).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will present safety, pharmacokinetics and preliminary anti-tumor effect of AVID100 in previously treated HNSCC, NSCLC and TNBC patients with documented EGFR-overexpression (NCT03094169). Data from the parallel development of an EGFR companion diagnostic test used to select for EGFR-overexpressing tumors will also be presented.

Details of the Presentations Are as Follows:

World ADC
Oral presentation by Forbius’ Chief Scientific Officer, Dr. Maureen O’Connor
Title: Development of AVID100, an Anti-EGFR ADC with a Novel Mechanism for Tumor Selective Cytotoxicity
Date: Thursday, Oct. 10
Time: 11:30 AM PT
Clinical Stream

AACR-NCI-EORTC
Poster presentation by Forbius’ Chief Development Officer, Dr. Robert Lutz
Title: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors
Date: Sunday, Oct. 27
Time: 12:30 – 4:00 PM ET
Location: Hall D, Hynes Convention Center
Clinical Trials Session
Abstract #A088
Link to online Program here (search for AVID100 to see abstract)